Latest Industry Insights

Clear Labs is a company focused on the latest technologies in molecular testing, machine learning, automation and bioinformatics – it develops fully automated next-generation sequencing and in vitro diagnostics solutions. Technology Networks had the pleasure of speaking with ClearLabs’ CEO Sasan Amini, to learn more about the company’s NGS-based COVID test, Clear Dx™.

For companies in the life sciences and pharma industry, a long-standing challenge is the need to digitize and make available legacy data for drug development workflows. At the same time, they must also incorporate the latest technologies into drug development and testing processes. In this article, Mark Spencer explores how companies can tackle these dual challenges with the help of informatics solutions.

Technology Networks recently spoke with iBio’s CEO and Chairman of the Board Thomas Isett, to learn more about the company’s efforts to develop a novel COVID-19 therapeutic called ACE2-Fc, as well as two vaccine candidates IBIO-200 and IBIO-201.

This article explores how next-generation sequencing (NGS) is being used to help track the spread and evolution of SARS-CoV-2, including pinpoint the different lineages of the virus and identifying patterns of its movement both globally as well as locally.

News of how innovations can assist scientists and their workflows is not uncommon, but claims of “industry revolutions”, however, tend to be a little less frequent. The Echo® MS System from SCIEX is touted as being one such revolution, we spoke to Neil Walsh to learn more.

In this piece, Ejvind Mørtz and Todd Stawicki explain why it’s critical that gene therapy products are free of host cell proteins and how this can be ensured in the production process, so that these next-generation drugs can fulfil their potential as one-shot cures for a range of diseases, from rare genetic conditions to cancer.

The ACE2 receptor has garnered significant attention for the wrong reasons over recent months. Could it point towards an exit route out of this pandemic? In an interview with Technology Networks, the renowned immunologist Professor Josef Penninger explains why he thinks so, and discusses the latest clinical data obtained from testing the soluble ACE2 receptor, APN01.

Between caring for patients and battling global pandemics, healthcare workers have a lot on their plate. How can healthcare workers make time to keep abreast of the latest literature in their field?

Technology Networks recently spoke to Dr Gary Keating, Chief Technical Officer at Hibergene Diagnostics, to learn more about LAMP technology and the advantages it could offer for COVID-19 testing. Gary also discussed some of the challenges faced when developing diagnostics and how the COVID-19 pandemic has impacted diagnostic design and manufacturing.

Technology Networks spoke to Dr Iswariya Venkataraman, Scientific Affairs Lead at EUROIMMUN US, to learn about the differences between the S and N proteins and what makes them suitable as target antigens in serology testing. Iswariya also discussed the findings and implications from a study which cautioned against the extensive use of tests that detect antibodies against the N protein only.